A venture capital firm involved in Lilly’s Mirror Portfolio, a concept created by Lilly to access innovation developed outside the company, has acquired two molecules and will oversee further development. The first is a molecule developed at a major academic institution that is being studied as a potential treatment for congestive heart failure. The second molecule, developed by Lilly, is being studied for its potential in bone healing and cancer. Chorus, Lilly’s virtual development organization...